Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | WNT3A | P56704 | 7/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CCR1 | P32246 | 1/20 | 0.45 |
| ▸ | CCR5 | P51681 | 1/20 | 0.45 |
| ▸ | CCR8 | P51685 | 1/20 | 0.45 |
| ▸ | METAP1 | P53582 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.45 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.45 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30144824 | 1.00 | CYP2A6 (0.50) | CYP2A6CNR2WNT3AGRM5KDM4E | |
| SCHEMBL21935795 | 0.79 | CYP2A6 (0.47) | CYP2A6CNR2WNT3AGRM5KDM4E | |
| SCHEMBL26551518 | 0.78 | PIK3CG (0.49) | CYP2A6CNR2WNT3AGRM5CYP1A2 | |
| SCHEMBL2698364 | 0.77 | ACHE (0.49) | WNT3A | |
| SCHEMBL18201427 | 0.77 | CYP2A6 (0.49) | CYP2A6CNR2WNT3AGRM5LMNA | |
| SCHEMBL21494145 | 0.77 | KDM4E (0.64) | CYP2A6CNR2WNT3AGRM5KDM4E | |
| SCHEMBL1068961 | 0.77 | KDM4E (0.64) | CYP2A6CNR2WNT3AGRM5KDM4E | |
| SCHEMBL23405927 | 0.76 | FABP1 (0.63) | WNT3AKDM4ELMNACYP1A2POLB | |
| SCHEMBL20641476 | 0.76 | RAB9A (0.66) | GRM5KDM4E | |
| SCHEMBL23405932 | 0.76 | GRM5 (0.64) | CNR2WNT3AGRM5KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023196975-A1 | COMPOUNDS THAT INTERACT WITH RAS SUPERFAMILY PROTEINS FOR TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, LLC (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230212138-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212138-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212138-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | US | disclosed |
| EP-4121424-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE | Akebia Therapeutics Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021188944-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE | AKEBIA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-4351941-A | Pyridinyl-pyridines | STERLING DRUG INC. (US) | 1982-09-28 | — | — | US | disclosed |
| US-4331672-A | 5-(Pyridinyl)pyridine-2-hydrazines, their preparation and their cardiotonic use | STERLING DRUG INC. (US) | 1982-05-25 | — | — | US | disclosed |
| US-4331672-A | 5-(Pyridinyl)pyridine-2-hydrazines, their preparation and their cardiotonic use | STERLING DRUG INC. (US) | 1982-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212138-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND THEIR USE | HIF1AN, EGLN3, EGLN2 | CYP2A6 2431/4885CNR2 3741/4885WNT3A 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.